Form 4: Cabaletta Bio Director Shawn Tomasello Granted 22,000 Stock Options

Cabaletta Bio, Inc. Director Shawn Tomasello was granted 22,000 stock options with an exercise price of $2.37, aligning his interests with shareholder value.

Summary

• Shawn Tomasello, a Director of Cabaletta Bio, Inc. (CABA), reported the acquisition of 22,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 9, 2025.
• Each stock option has an exercise price of $2.37.
• The options entitle the holder to purchase 22,000 shares of Cabaletta Bio Common Stock.
• The derivative securities were acquired at a price of $0, indicating a grant rather than a purchase.
• These options will vest in full upon the earlier of June 9, 2026, or the date of the next annual meeting of the Corporation's stockholders.
• The options have an expiration date of June 8, 2035.
• Following this transaction, Shawn Tomasello directly beneficially owns 22,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reports a routine insider transaction (stock option grant) which is generally viewed as a neutral to slightly positive event, as it aligns director incentives with shareholder interests without indicating any immediate operational or financial issues.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and performance from the director.

Future Outlook

The granted stock options are set to vest in full upon the earlier of June 9, 2026, or the date of the next annual meeting of the Corporation's stockholders, and will expire on June 8, 2035.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to incentivize performance and align leadership interests with shareholder value.

Related Party Transactions

• The grant of stock options to Director Shawn Tomasello by Cabaletta Bio, Inc. constitutes a related party transaction, as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The stock options will vest based on the specified conditions (earlier of June 9, 2026, or the next annual meeting).
• Shawn Tomasello may choose to exercise the options once vested, prior to their expiration date of June 8, 2035.

Key Dates

Keywords

Cabaletta Bio, CABA, Form 4, Stock Option Grant, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership